- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03785899
Automatic Oxygen Control (SPOC) in Preterm Infants (optimalSPOC)
Automatic Oxygen Control (SPOC) in Preterm Infants - Evaluation of a Revised Algorithm and Effect of Averaging Time of Pulse Oximetry Signal
Single-center, randomised controlled, cross-over clinical trial in preterm infants born at gestational age below 34+1/7 weeks receiving supplemental oxygen and respiratory support (continous positive airway pressure (CPAP) or non-invasive ventilation (NIV) or invasive ventilation (IV)). Routine manual control (RMC) of the fraction of inspired oxygen (FiO2) will be tested against RMC supported by automatic control (SPOC) with "old"-algorithm and RMC supported by CLAC with "new"-algorithm.
The first primary hypothesis is, that the use of the "new" algorithm results in more time within arterial oxygen saturation (SpO2) target range compared to RMC only. The a-priori subordinate hypothesis is, that the new algorithm results in more time within SpO2 target range compared to SPOCold.
The second primary hypothesis is, that the use of 2 seconds averaging time of the SpO2 Signal results in more time within arterial oxygen saturation (SpO2) target range compared to the use of 8 seconds averaging interval of the SpO2 signal.
Study Overview
Status
Intervention / Treatment
Detailed Description
BACKGROUND AND OBJECTIVE In preterm infants receiving supplemental oxygen, routine manual control (RMC) of the fraction of inspired oxygen (FiO2) is often difficult and time consuming. The investigators developed a system for closed-loop automatic control (SPOC) of the FiO2. The objective of this study is to test a revised, "new" algorithm with 3 adaptions against the former "old" algorithm and against RMC. The 3 adaptions are:
- Faster re-adjustment to baseline-FiO2 (baseline FiO2: mean FiO2 during the previous 5min)
- Delayed reduction of FiO2 below baseline FiO2
- Maximum FiO2 adjustable by user
The first primary hypothesis is, that the application of SPOCnew in addition to RMC results in more time within arterial oxygen saturation (SpO2) target range compared to RMC only. The a-priori subordinate hypothesis is, that the revised algorithm is more effective as the old algorithm to maintain the SpO2 in the target range.
The second primary hypothesis is, that the shortening of averaging time used for the SpO2 Signal from 8 seconds to 2 seconds results in more time within SpO2 target range for both, SPOCnew and SPOCold.
Further hypotheses for exploratory testing are, that the SPOC new algorithm will achieve a lower proportion of time with SpO2 above and below the target range, hyper- and hypoxia and an improved stability of cerebral oxygenation (measured as rcStO2 and rcFtO2E determined by Near-infrared spectroscopy) compared with SPOCold and RMC. Reduction of staff workload (estimated by number of manual adjustments per hour) by SPOC. Validation of a clinical scoring tool to monitor severity of apnea of prematurity.
STUDY DESIGN The Study is designed as a single-center, randomized controlled, cross-over clinical trial in preterm infants receiving mechanical ventilation or nasal continuous positive airway pressure or non-invasive ventilation and supplemental oxygen (FiO2 above 0.21). Within a 30-hour period the investigators will compare 6 hours of RMC with 12-hour periods of RMC supported by SPOCnew algorithm or SPOCold algorithm, respectively. During intervals with SPOC control the SpO2 Signal averaging time will be 2 second or 8seconds , respectively, for 6 hours each.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Christoph E Schwarz, MD
- Phone Number: 84742 +49707129-0
- Email: c.schwarz@med.uni-tuebingen.de
Study Contact Backup
- Name: Axel R Franz, MD
- Phone Number: 83791 +49707129-0
- Email: axel.franz@med.uni-tuebingen.de
Study Locations
-
-
-
Tübingen, Germany, 72076
- Recruiting
- Department of Neonatology, University Children's Hospital
-
Contact:
- Axel R Franz, MD
- Phone Number: 83791 +49707129-0
- Email: axel.franz@med.uni-tuebingen.de
-
Contact:
- Christoph E Schwarz, MD
- Phone Number: 80895 +49707129-0
- Email: c.schwarz@med.uni-tuebingen.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- gestational age at birth <34+1/7weeks and
- invasive mechanical ventilation OR noninvasive ventilation OR continous positive airway pressure support and
- Fraction of inspired oxygen above 0.21 before inclusion and
- more than 2 hypoxaemic events (arterial oxygen saturation below 80%) within 8 hours before inclusion and
- parental written informed consent
Exclusion Criteria (any of the following):
- congenital pulmonary anomalies
- congenital heart defects influencing SpO2 (i.e. cyanotic heart defects)
- right-to -left shunt through a PDA
- Severe neonatal complications during study period (sepsis, necrotising enterocolitis)
- diaphragmatic hernia or other diaphragmatic disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: RMC only
routine manual control (RMC) of the fraction of inspired oxygen (FIO2)
|
|
Experimental: SPOCnew and 2s SpO2 averaging
routine manual control (RMC) + automatic oxygen control (SPOC) with "new" algorithm of the fraction of inspired oxygen (FIO2). The SpO2 signal averaging time is 2s. |
SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2).
The revised "new" algorithm is turned on.
The arterial saturation (SPO2) will be averaged over 2s.
|
Experimental: SPOCnew and 8s SpO2 averaging
routine manual control (RMC) + automatic oxygen control (SPOC) with "new" algorithm of the fraction of inspired oxygen (FIO2). The SpO2 signal averaging time is 8s. |
SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2).
The revised "new" algorithm is turned on.
The arterial saturation (SPO2) will be averaged over 8s.
|
Active Comparator: SPOCold and 2s SpO2 averaging
routine manual control (RMC) + automatic oxygen control (SPOC) with "old" algorithm of the fraction of inspired oxygen (FIO2). The SpO2 signal averaging time is 2s. |
The arterial saturation (SPO2) will be averaged over 2s.
SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2).
The former "old" algorithm is turned on.
|
Active Comparator: SPOCold and 8s SpO2 averaging
routine manual control (RMC) + automatic oxygen control (SPOC) with "old" algorithm of the fraction of inspired oxygen (FIO2). The SpO2 signal averaging time is 8s. |
The arterial saturation (SPO2) will be averaged over 8s.
SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2).
The former "old" algorithm is turned on.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of time with SpO2 within target range
Time Frame: 30 hours
|
Comparison of proportion of time with SpO2 within target range and time above target range if no supplemental oxygen was administered at that time and within the preceding 30sec between the five treatment modalities
|
30 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Time with SpO2 above target range
Time Frame: 30 hours
|
Comparison of proportion of time with SpO2 above target range if supplemental oxygen was administered at that time or within the preceding 30sec .
|
30 hours
|
Proportion of Time with SpO2 below target range
Time Frame: 30 hours
|
Comparison of proportion of time with SpO2 below target range.
|
30 hours
|
Proportion of Time with Hypoxia
Time Frame: 30 hours
|
Comparison of proportion of time with SpO2 below 80%.
|
30 hours
|
Proportion of Time with Hyperoxia
Time Frame: 30 hours
|
Comparison of proportion of time with SpO2 above 97% if supplemental oxygen was administered at that time or at anytime during the previous 30 seconds.
|
30 hours
|
Stability of cerebral oxygenation
Time Frame: 30 hours
|
"Area under the curve" of cerebral tissue saturation or fraction of tissue oxygen extraction outside of the infants Median +- 5% or outside of the "safe" interval of 55-80% rcStO2.
|
30 hours
|
Severe hypoxemic episodes
Time Frame: 30 hours
|
Rate of episodes with SpO2 <80% for at least 60seconds
|
30 hours
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Staff workload
Time Frame: 30 hours
|
number of manual adjustments of inspired oxygen per time
|
30 hours
|
Validation of clinical Apnea Score
Time Frame: 30 hours
|
Validation of a modified Apnea Score monitored by clinical staff by correlation between Score and other secondary outcomes.
The modified Apnoea Score aims to quantify the burden from apnoea-bradycardia-syndrome by assigning 1-2-4 or 8 points according to event severity.
Points are summed up during each treatment period in this study.
|
30 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Christoph E Schwarz, MD, University of Tubingen, University Hospital, Dept. Neonatology
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- optimalSPOC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ventilator Lung; Newborn
-
University of Illinois College of Medicine at PeoriaOSF Healthcare System; Children's Hospital of IllinoisRecruiting
-
Rambam Health Care CampusCompletedVentilator Lung; NewbornIsrael
-
Rajeev KumarRecruitingFeeding Patterns | Ventilator Lung; Newborn | Prematurity; ExtremeUnited States
-
Hospital de Clinicas de Porto AlegreRecruitingMechanical Ventilation Complication | Caffeine | Ventilator Lung; NewbornBrazil
-
Alexandria UniversityCompletedHemodynamic Instability | Echocardiography | Ventilator Lung; NewbornEgypt
-
University Hospital, LilleCompletedVentilator Lung; NewbornFrance
-
Ministry of Health, Saudi ArabiaNot yet recruitingRespiratory Disease | Prematurity | Ventilator Lung; Newborn
-
University Hospital TuebingenJohannes Gutenberg University Mainz; Heinen und Löwenstein GmbH & Co. KGCompletedInfant Respiratory Distress Syndrome | Ventilator Lung; NewbornGermany
-
Gazi UniversityCompletedVentilator Induced Lung Injury | Respiratory Distress, NewbornTurkey
-
King Fahad Armed Forces HospitalCompletedRespiratory Failure | Prematurity | Ventilator Lung; NewbornSaudi Arabia